Literature DB >> 17955044

Unanswered questions regarding the management of sunitinib-induced hypothyroidism.

David Garfield1, Aleck Hercbergs, Paul Davis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17955044     DOI: 10.1038/ncponc0998

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


× No keyword cloud information.
  6 in total

Review 1.  Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.

Authors:  Rebecca L Brown
Journal:  Target Oncol       Date:  2011-11-19       Impact factor: 4.493

Review 2.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

Review 3.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

4.  Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors.

Authors:  P Schöffski; D H Garfield; A Hercbergs; P Wolter
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

Review 5.  Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Authors:  Francesco Torino; Salvatore Maria Corsello; Raffaele Longo; Agnese Barnabei; Giampietro Gasparini
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

Review 6.  Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment.

Authors:  Hala Ahmadieh; Ibrahim Salti
Journal:  Biomed Res Int       Date:  2013-10-27       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.